PeerView Clinical Pharmacology CME/CNE/CPE Video

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share






Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC


Go online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology, Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations, Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials.


fyyd: Podcast Search Engine
share








 August 5, 2020  1h0m